Please use this identifier to cite or link to this item:
https://dspace.uzhnu.edu.ua/jspui/handle/lib/44971
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Petakh P., Петах Павло Владиславович P. | - |
dc.contributor.author | Kamyshna I., Камишна І. | - |
dc.contributor.author | Nykyforuk A., Никифорук Андрій Ярославович A. | - |
dc.contributor.author | et al. | - |
dc.date.accessioned | 2022-10-18T15:35:30Z | - |
dc.date.available | 2022-10-18T15:35:30Z | - |
dc.date.issued | 2022 | - |
dc.identifier.citation | Petakh, P.; Kamyshna, I.; Nykyforuk, A.; Yao, R.; Imbery, J.F.; Oksenych, V.; Korda, M.; Kamyshnyi, A. Immunoregulatory Intestinal Microbiota and COVID-19 in Patients with Type Two Diabetes: A Double-Edged Sword. Viruses 2022, 14, 477. | uk |
dc.identifier.issn | 1999-4915 | - |
dc.identifier.uri | https://dspace.uzhnu.edu.ua/jspui/handle/lib/44971 | - |
dc.description.abstract | Coronavirus disease 2019, or COVID-19, is a major challenge facing scientists worldwide. Alongside the lungs, the system of organs comprising the GI tract is commonly targeted by COVID-19. The dysbiotic modulations in the intestine influence the disease severity, potentially due to the ability of the intestinal microbiota to modulate T lymphocyte functions, i.e., to suppress or activate T cell subpopulations. The interplay between the lungs and intestinal microbiota is named the gut–lung axis. One of the most usual comorbidities in COVID-19 patients is type 2 diabetes, which induces changes in intestinal microbiota, resulting in a pro-inflammatory immune response, and consequently, a more severe course of COVID-19. However, changes in the microbiota in this comorbid pathology remain unclear. Metformin is used as a medication to treat type 2 diabetes. The use of the type 2 diabetes drug metformin is a promising treatment for this comorbidity because, in addition to its hypoglycemic action, it can increase amount of intestinal bacteria that induce regulatory T cell response. This dual activity of metformin can reduce lung damage and improve the course of the COVID-19 disease. | uk |
dc.language.iso | en | uk |
dc.publisher | Viruses | uk |
dc.subject | type 2 diabetes;metformin; COVID-19; SARS-CoV-2; intestinal microbiota; immunoregulation | uk |
dc.subject | type 2 diabetes;metformin; COVID-19; SARS-CoV-2; intestinal microbiota; immunoregulation | uk |
dc.title | Immunoregulatory Intestinal Microbiota and COVID-19 in Patients with Type Two Diabetes: A Double-Edged Sword | uk |
dc.type | Text | uk |
dc.pubType | Стаття | uk |
Appears in Collections: | Наукові публікації кафедри біохімії, фармакології та фізичних методів лікування |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
viruses-14-00477-v4.pdf | 2.19 MB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.